RSK2 promotes melanoma cell proliferation and vemurafenib resistance via upregulating cyclin D1

• Autores principales: Hai-Zhou Wu (Autor), Lan-Ya Li (Autor), Shi-Long Jiang (Autor), Yi-Zhi Li (Autor), Xiao-Mei Shi (Autor), Xin-Yuan Sun (Autor), Zhuo Li (Autor), Yan Cheng (Autor)
• Formato: Libro
• Publicado: Frontiers Media S.A., 2022-09-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

BRAF inhibitors are commonly used in targeted therapies for melanoma patients harboring BRAFV600E mutant. Despite the benefit of vemurafenib therapy, acquired resistance during or after treatment remains a major obstacle in BRAFV600E mutant melanoma. Here we found that RSK2 is overexpressed in melan...